Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
We have shown by transient transfection assays that c-Abl increases expression of a c-myc promoter construct although to a lesser extent than v-Abl. c-Abl has been reported to bind to a specific DNA sequence, the EP element, in the hepatitis B virus enhancer. A similar sequence exists in the promoter region of the c-myc gene, and we have identified a potential protein binding site in this region by in vivo footprinting. Gel shift analysis demonstrated that the hepatitis B virus enhancer and c-myc sites yield identical complexes. To determine whether c-Abl activates c-myc transcription by binding directly to the promoter region, several experiments were performed. Mutation of the EP site in the c-myc promoter had no effect on transcriptional activation of c-myc by c-Abl. Next, we demonstrated that the DNA binding domain of c-Abl was not required for the transcriptional activation of c-myc. Finally, by Western blot analysis, we have determined that c-Abl is not present in the gel shift complexes formed by either the hepatitis B virus enhancer or c-myc promoter. We conclude that c-Abl activates c-myc transcription indirectly with no requirement for DNA binding by c-Abl. We also find no evidence for the interaction of c-Abl with the EP sequence of either the hepatitis B virus enhancer or the c-myc promoter.
View details for Web of Science ID A1994PK97300078
View details for PubMedID 8063836